Chrissy Metz told Us Weekly on September 16 that she is unbothered by criticism of her GLP-1 weight loss journey, saying people are going to criticize you no matter what you do. The This Is Us alum, 45, spoke while discussing her partnership with Ro, and that partnership is the first thing a reader should know before weighing anything else in the interview.

Metz announced on the Today show last month that she had started using Ro, which Us Weekly describes as a GLP-1 medication commonly used for weight loss. She made the comments around a dinner she cohosted with Ro's Chief Medical Officer Dr. Melynda Barnes at The Mark Restaurant in New York, which is to say this is a promotional appearance, not a clinical disclosure.

From skeptic to customer

The most interesting thing Metz says is that she spent a long time refusing. "I was skeptical for quite some time," she told Us, adding that she did "a lot of extensive research" and that access was initially hard. She said she decided to try the medication after speaking with friends who had their own success with Ro.

What she praises about Ro specifically is logistics: delivery to the door, and the ability to chat with nurses and doctors through an app. That is a distribution pitch rather than a pharmacological one, and it is worth separating the two.

What she reports

Metz said she has had "mild side effects" she called manageable, and that her labs and blood work have both "significantly improved" since she began her doses. She also said she feels more mobile, sleeps better, and completed eight shows a week on Broadway, which she attributed in part to decreased inflammation and to the quieting of "food noise," the obsessive thinking about food she said she never expected the medication to touch.

Where the evidence stops

All of that is one person's account, given in the course of a commercial partnership. No trial, no published data, no clinician's assessment of her case appears anywhere in the interview, and Barnes is not quoted on any of it. The food noise observation is the part worth watching, because it is the mechanism patients keep raising and the one the marketing rarely leads with.

Bottom line

Metz's own framing is the honest one: not one thing is for everybody. She is describing what happened to her, and that is the entire claim.